DrugInformer Search

Diffuse Panbronchiolitis : Clarithromycin Vs. Erythromycin


Diffuse panbronchiolitis (DPB) is an inflammatory lung disease of unknown cause. It is a severe, progressive form of bronchiolitis, which is inflammation of the bronchioles. The term "diffuse" refers to the lesions which appear throughout both lungs, while "panbronchiolitis" refers to the inflammation found in all layers of the respiratory bronchioles, both terms describing a common pathology for the disease. DPB mainly causes severe inflammation of the respiratory bronchioles (the section of the bronchioles involved in gas exchange), nodule-like lesions in respiratory and terminal bronchioles, and intense coughing with large amounts of sputum production.

Read more on Wikipedia

Compare Drugs

Please add a drug to the list to compare them side by side.
Add a new Drug

* Warning: The facts and figures contained in these reports are accurate to the best of our capability; however, our metrics are only meant to augment your medical knowledge, and should never be used as the sole basis for selecting a new medication. As with any medical decision, be sure to work with your doctor to ensure the best choices are made for your condition.

* About FAERS: The FDA Adverse Event Reporting System (FAERS) is used by FDA for activities such as looking for new safety concerns that might be related to a marketed product, evaluating a manufacturer's compliance to reporting regulations and responding to outside requests for information. Reporting of adverse events is a voluntary process, and not every report is sent to FDA and entered into FAERS. The FAERS database may contain duplicate reports, the report quality is variable, and many factors may influence reporting (e.g., media attention, length of time a drug is marketed, market share). For these reasons, FAERS case reports cannot be used to calculate incidence or estimates of risk for a particular product or compare risks between products.